Pierre Jacquet and Jonathan Hodgson
Executives at fledgling biotech and specialty pharma companies strive to develop lead products with blockbuster potential in the hopes that...
For biopharma, launching first products, and especially sudden profitability, doesn't necessarily predict which companies will succeed. Instead, an examination of stock market success shows the need to bring a succession of drugs, or at least additional indications, into clinical trials-mostly through aggressive deal-making.
Pierre Jacquet and Jonathan Hodgson
Executives at fledgling biotech and specialty pharma companies strive to develop lead products with blockbuster potential in the hopes that...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.